The Dawn of a New Era in Heart Failure Treatment: BioCardia’s CardiAMP Heart Failure II Phase 3 Pivotal Study

BioCardia Logo

In an exciting development for the field of cardiovascular medicine, BioCardia, Inc., a pioneering biotechnology company, has announced the activation of the CardiAMP Heart Failure II Phase 3 pivotal study. This groundbreaking study, recently greenlit by the FDA, represents a significant leap forward in the treatment of ischemic heart failure through advanced cell therapy techniques. […]